[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Harrow Inc (HROW)

Harrow Inc (HROW)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,441,797
  • Shares Outstanding, K 37,275
  • Annual Sales, $ 272,300 K
  • Annual Income, $ -5,140 K
  • EBIT $ 20 M
  • EBITDA $ 43 M
  • 60-Month Beta 0.26
  • Price/Sales 5.38
  • Price/Cash Flow 43.34
  • Price/Book 49.25

Options Overview Details

View History
  • Implied Volatility 81.93% (+0.58%)
  • Historical Volatility 55.66%
  • IV Percentile 72%
  • IV Rank 52.94%
  • IV High 110.75% on 08/07/25
  • IV Low 49.50% on 08/29/25
  • Expected Move (DTE 22) 0.00 (0.00%)
  • Put/Call Vol Ratio 2.45
  • Today's Volume 38
  • Volume Avg (30-Day) 545
  • Put/Call OI Ratio 0.19
  • Today's Open Interest 41,927
  • Open Int (30-Day) 45,071
  • Expected Range 38.68 to 38.68

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.23
  • Number of Estimates 3
  • High Estimate $0.01
  • Low Estimate $-0.50
  • Prior Year $0.24
  • Growth Rate Est. (year over year) -195.83%

Price Performance

See More
Period Period Low Period High Performance
1-Month
36.25 +6.70%
on 07/28/26
47.50 -18.57%
on 07/17/26
-2.47 (-6.00%)
since 06/29/26
3-Month
28.54 +35.53%
on 05/13/26
47.50 -18.57%
on 07/17/26
-1.56 (-3.88%)
since 04/29/26
52-Week
28.54 +35.53%
on 05/13/26
54.85 -29.48%
on 01/07/26
+4.15 (+12.02%)
since 07/29/25

Most Recent Stories

More News
Harrow To Report Second Quarter 2026 Financial Results After Market Close on August 10, 2026

NASHVILLE, Tenn., July 27, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its financial...

HROW : 38.68 (-1.63%)
Samsung Bioepis and Harrow Present Interim Data from a Large-Scale Post-Marketing Surveillance Study on SB11 (BYOOVIZ® / AMELIVU®), a Biosimilar to Lucentis (ranibizumab), at ASRS 2026

A real-world PMS study based on a large population demonstrates comparable safety profile of SB11 (BYOOVIZ ® / AMELIVU ® ) to reference ranibizumab In treatment-naïve patients,...

HROW : 38.68 (-1.63%)
Harrow Highlights Growing Clinical Evidence Supporting IHEEZO® and BYOOVIZ® at ASRS 2026 Annual Meeting

NASHVILLE, Tenn., July 20, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the presentation of three studies...

HROW : 38.68 (-1.63%)
Harrow Announces Commercial Launch of BYOOVIZ® in the United States

NASHVILLE, Tenn., July 01, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the commercial launch of BYOOVIZ®...

HROW : 38.68 (-1.63%)
Harrow Re-Launches VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1% for Vernal Keratoconjunctivitis, Addressing Significant Unmet Need in Pediatric Eyecare

VERKAZIA is now supported by a comprehensive commercial strategy focused on physician education, patient access, and affordability initiatives to ensure dependable supply and remove access barriers ...

HROW : 38.68 (-1.63%)
Harrow to Present at William Blair’s 46th Annual Growth Stock Conference

NASHVILLE, Tenn., May 27, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will present...

HROW : 38.68 (-1.63%)
Harrow Q1 Earnings Call Highlights

Harrow (NASDAQ:HROW) executives said the company’s first-quarter results were weighed down by a discrete revenue issue tied to VEVYE coverage and high-deductible patients, but management repeatedly emphasized...

HROW : 38.68 (-1.63%)
Harrow: Q1 Earnings Snapshot

Harrow: Q1 Earnings Snapshot

HROW : 38.68 (-1.63%)
Harrow Announces First Quarter 2026 Financial Results

First Quarter 2026 and Selected Highlights:  VEVYE ® delivered record new and total prescription performance (despite an approximate 18% decline in the overall branded dry eye category) VEVYE...

HROW : 38.68 (-1.63%)
Harrow's Ophthalmic Portfolio Expansion Meets Its First Real Profitability Test

Barchart Research What to Expect from HROW Earnings HROW Generated May 8, 2026 Current Price $38.23 EPS Estimate $$-0.43 Consensus Rating Strong Buy Average Move 20.02% Harrow's Ophthalmic Portfolio Expansion...

HROW : 38.68 (-1.63%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Harrow Inc. is an eyecare pharmaceutical company. It engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products principally for the U.S. market. Harrow Inc., formerly known as Harrow Health Inc., is based in NASHVILLE, Tenn.

See More

Key Turning Points

3rd Resistance Point 40.81
2nd Resistance Point 40.27
1st Resistance Point 39.47
Last Price 38.68
1st Support Level 38.13
2nd Support Level 37.59
3rd Support Level 36.79

See More

52-Week High 54.85
Fibonacci 61.8% 44.80
Fibonacci 50% 41.70
Last Price 38.68
Fibonacci 38.2% 38.59
52-Week Low 28.54

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.